Navigation Links
Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
Date:5/17/2013

SAN DIEGO, May 17, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the UBS Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, May 22nd at 11 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2019)... ... June 19, 2019 , ... INDIGO Biosciences, Inc. (INDIGO), ... announced the addition of the Human MDR-1 / P-Glycoprotein Drug Interaction Assay ... and allows researchers to perform critical toxicology testing previously available only through contract ...
(Date:6/18/2019)... ... June 18, 2019 , ... Officials with American Physician ... are pleased to announce the acquisition of Leading Edge Medical Associates (LEMA), a ... physicians and 9 advanced practice clinicians care for 115,000 emergency department patients annually ...
(Date:6/16/2019)... ... June 15, 2019 , ... Lycotec Ltd, a Cambridge ... study on its new prebiotic, LycoBiotic™, which is 1,000 – 4,000 stronger than ... which were based on a proprietary composition of GA lycopene, specially developed for ...
Breaking Medicine Technology:
(Date:6/16/2019)... ... June 15, 2019 , ... All families go through tough times. When parents ... and lack of a support network, they may be unable to care for their ... the home and place them with a relative, familiar caregiver or foster family while ...
(Date:6/14/2019)... ... June 14, 2019 , ... ... Pink Bag Event® scheduled for Saturday, July 13th. UBCF is thrilled to return ... directly impacted by breast cancer. This second event was added after an overwhelming ...
(Date:6/13/2019)... ... June 13, 2019 , ... Endometriosis is a painful, inflammatory disease that occurs when ... , Painful periods , Heavy bleeding , Irregular menstruation , ... , Women’s Excellence uses the latest and newest treatment protocols in dealing with the ...
(Date:6/13/2019)... ... June 13, 2019 , ... ... 30 Second Test (BL30SEC) has been accepted by the 2019 National Conference of ... Appendix N requirements. , The Charm BL30SEC test was validated by third ...
(Date:6/13/2019)... ... ... Hard money lenders like Monroe Funding Corporation are able to respond and approve ... If the documentation and collateral are immediately available, it’s possible to receive approval and ... with a traditional lender, which allows loans to be customized and adjusted based on ...
Breaking Medicine News(10 mins):